Activity 1: Biobank collection and control

 

Background/Aim:

In order to be able to pursue the Alzheimer’s disease projects, we need to evaluate the various strategies directly on patient samples. Over the years, an extensive biobank has been established. To date, plasma samples from approximately 500 patients with Alzheimer’s disease and various other dementia disorders have been collected. Among these, 100 samples come from patients with mild cognitive impairment, many of whom describe an early disease state. Such individuals are particularly suitable to study early changes in Alzheimer’s disease. In addition, we have plasma from 400 healthy control subjects. At Department of Clinical Chemistry of Uppsala University Hospital a large number of plasma and CSF samples are being stored.

Also, we have access to more than 200 CSF samples from cases with Alzheimer’s disease, other dementias, mild cognitive impairment and healthy control subjects. We have established a biobank for neuropathological specimens, i.e. brain tissue from deceased patients. This tissue is collected according to modern brain banking principles, where one brain hemisphere is fixed in formalin and mainly used for diagnostic purposes whereas the other half is fresh-frozen and stored at –80°C. Due to a very efficient handling procedure most of these tissues have a post-mortem interval < ten hours.

The aim of this activity is to continue the tissue collection and to treat the samples as equal as possible before storage.

 

 

 

 

Project leader:

 

 

 

Participants:

  • Anders Larsson (UAS)

 

 

PARTNERS
Uppsala Berzelii Technology Centre for Neurodiagnostics | Email info@berzelii.uu.se